Novo Nordisk A/S
NVO50.370USD
+0.190+0.38%
Cierre 12/15, 16:00（ET）Cotizaciones retrasadas 15 min
169.45BCap. mercado
14.59P/E TTM
Más Datos de Novo Nordisk A/S Compañía
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Información de Novo Nordisk A/S
Símbolo de cotizaciónNVO
Nombre de la empresaNovo Nordisk A/S
Fecha de salida a bolsaMay 17, 1974
Director ejecutivoDoustdar (Maziar Mike)
Número de empleados76302
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 17
DirecciónNovo Alle 1
CiudadBAGSVAERD
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísDenmark
Código postal2880
Teléfono4544448888
Sitio Webhttps://www.novonordisk.com/
Símbolo de cotizaciónNVO
Fecha de salida a bolsaMay 17, 1974
Director ejecutivoDoustdar (Maziar Mike)
Ejecutivos de Novo Nordisk A/S
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Cees de Jong
Dr. Cees de Jong
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Tania Sabroe
Ms. Tania Sabroe
Executive Vice President - People, Organisation & Corporate Affairs
Executive Vice President - People, Organisation & Corporate Affairs
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President, Chief Scientific Officer, Research & Development
Executive Vice President, Chief Scientific Officer, Research & Development
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Cees de Jong
Dr. Cees de Jong
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
--
--
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Total GLP-1
5.83B
49.92%
Obesity (Wegovy®)
2.97B
25.41%
Fast-acting insulin
689.86M
5.91%
Long-acting insulin
678.47M
5.81%
Rare blood disorders
470.23M
4.03%
Otro
1.04B
8.92%
Por regiónUSD
Nombre
Ganancia
Proporción
USA
6.53B
55.90%
Canada
2.50B
21.40%
Emerging Markets
1.15B
9.82%
APAC
852.83M
7.31%
Region China
651.28M
5.58%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Total GLP-1
5.83B
49.92%
Obesity (Wegovy®)
2.97B
25.41%
Fast-acting insulin
689.86M
5.91%
Long-acting insulin
678.47M
5.81%
Rare blood disorders
470.23M
4.03%
Otro
1.04B
8.92%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Capital International Investors
0.53%
Loomis, Sayles & Company, L.P.
0.48%
Putnam Investment Management, L.L.C.
0.41%
Fidelity Management & Research Company LLC
0.38%
Fisher Investments
0.31%
Otro
97.91%
Accionistas
Accionistas
Proporción
Capital International Investors
0.53%
Loomis, Sayles & Company, L.P.
0.48%
Putnam Investment Management, L.L.C.
0.41%
Fidelity Management & Research Company LLC
0.38%
Fisher Investments
0.31%
Otro
97.91%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
4.66%
Investment Advisor/Hedge Fund
2.41%
Research Firm
0.92%
Hedge Fund
0.38%
Pension Fund
0.33%
Bank and Trust
0.20%
Insurance Company
0.19%
Family Office
0.02%
Family Office
0.02%
Otro
90.87%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
2793
305.60M
9.08%
-33.91M
2025Q2
2754
330.35M
9.82%
-31.19M
2025Q1
2769
336.08M
9.99%
-21.71M
2024Q4
2676
348.53M
10.35%
+330.19K
2024Q3
2529
339.29M
10.15%
-6.04M
2024Q2
2456
341.24M
10.21%
+6.87M
2024Q1
2291
330.25M
9.75%
+10.89M
2023Q4
2037
314.57M
9.30%
+1.47M
2023Q3
1826
307.14M
8.91%
+4.22M
2023Q2
1692
293.83M
8.50%
+768.69K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital International Investors
11.62M
0.35%
+2.11M
+22.18%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
12.58M
0.37%
+187.79K
+1.52%
Jun 30, 2025
Fidelity Management & Research Company LLC
12.93M
0.38%
+3.95M
+44.01%
Jun 30, 2025
Fisher Investments
11.00M
0.33%
-870.32K
-7.33%
Jun 30, 2025
Folketrygdfondet
10.09M
0.3%
+572.63K
+6.01%
Jun 30, 2025
Managed Account Advisors LLC
8.81M
0.26%
+195.59K
+2.27%
Jun 30, 2025
Fayez Sarofim & Co.
10.50M
0.31%
-708.84K
-6.32%
Jun 30, 2025
Everett Harris & Co.
6.39M
0.19%
-13.84K
-0.22%
Jun 30, 2025
Parametric Portfolio Associates LLC
6.23M
0.19%
+587.70K
+10.42%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Roundhill GLP-1 & Weight Loss ETF
15.04%
VanEck Pharmaceutical ETF
14.55%
Amplify Weight Loss Drug & Treatment ETF
9.51%
The Opal International Dividend Income ETF
3.79%
TrueShares Low Volatility Equity Income ETF
3.21%
First Trust WCM International Equity ETF
2.68%
Invesco International Dividend Achievers ETF
1.8%
Putnam Focused Large Cap Value ETF
1.16%
SP Funds S&P World (ex-US) ETF
1.05%
ActivePassive International Equity ETF
0.95%
Ver más
Roundhill GLP-1 & Weight Loss ETF
Proporción15.04%
VanEck Pharmaceutical ETF
Proporción14.55%
Amplify Weight Loss Drug & Treatment ETF
Proporción9.51%
The Opal International Dividend Income ETF
Proporción3.79%
TrueShares Low Volatility Equity Income ETF
Proporción3.21%
First Trust WCM International Equity ETF
Proporción2.68%
Invesco International Dividend Achievers ETF
Proporción1.8%
Putnam Focused Large Cap Value ETF
Proporción1.16%
SP Funds S&P World (ex-US) ETF
Proporción1.05%
ActivePassive International Equity ETF
Proporción0.95%
Dividendos
Un total de
21.09B
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Aug 06, 2025
NVO.NB Interim Cash Dividend of gross USD 0.58432 paid on Aug 26, 2025 going ex on Aug 18, 2025
Aug 18, 2025
Aug 26, 2025
Aug 18, 2025
Feb 06, 2025
NVO.NB Final Cash Dividend of gross USD 1.142561 paid on Apr 08, 2025 going ex on Mar 31, 2025
Mar 31, 2025
Apr 08, 2025
Mar 31, 2025
Aug 06, 2024
NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Aug 26, 2024
Aug 16, 2024
Jan 31, 2024
NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024
Mar 25, 2024
Apr 02, 2024
Mar 22, 2024
Aug 10, 2023
NVO.NB Interim Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023
Aug 21, 2023
Aug 29, 2023
Aug 18, 2023
Feb 02, 2023
NVO.NB Final Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023
Mar 27, 2023
Apr 04, 2023
Mar 24, 2023
Aug 04, 2022
NVO.NB Interim Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022
Aug 15, 2022
Aug 23, 2022
Aug 12, 2022
Mar 02, 2022
NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022
Mar 28, 2022
Apr 05, 2022
Mar 25, 2022
Aug 05, 2021
NVO.NB Interim Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021
Aug 17, 2021
Aug 25, 2021
Aug 16, 2021
Feb 22, 2021
NVO.NB Final Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021
Mar 29, 2021
Apr 07, 2021
Mar 26, 2021
Ver más
División de acciones
Fecha
Tipo
Relación
Aug 14, 2023
Split
1→2
Fecha
Tipo
Relación
Aug 14, 2023
Split
1→2
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Novo Nordisk A/S?
Los cinco principales accionistas de Novo Nordisk A/S son:
Capital International Investors posee 11.62M acciones, lo que representa el 0.35% del total de acciones.
Loomis, Sayles & Company, L.P. posee 12.58M acciones, lo que representa el 0.37% del total de acciones.
Fidelity Management & Research Company LLC posee 12.93M acciones, lo que representa el 0.38% del total de acciones.
Fisher Investments posee 11.00M acciones, lo que representa el 0.33% del total de acciones.
Folketrygdfondet posee 10.09M acciones, lo que representa el 0.30% del total de acciones.
Capital International Investors posee 11.62M acciones, lo que representa el 0.35% del total de acciones.
Loomis, Sayles & Company, L.P. posee 12.58M acciones, lo que representa el 0.37% del total de acciones.
Fidelity Management & Research Company LLC posee 12.93M acciones, lo que representa el 0.38% del total de acciones.
Fisher Investments posee 11.00M acciones, lo que representa el 0.33% del total de acciones.
Folketrygdfondet posee 10.09M acciones, lo que representa el 0.30% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Novo Nordisk A/S?
Los tres principales tipos de accionista de Novo Nordisk A/S son:
Capital International Investors
Loomis, Sayles & Company, L.P.
Putnam Investment Management, L.L.C.
Capital International Investors
Loomis, Sayles & Company, L.P.
Putnam Investment Management, L.L.C.
¿Cuántas instituciones poseen acciones de Novo Nordisk A/S (NVO)?
A fecha de 2025Q3, 2793 instituciones poseen acciones de Novo Nordisk A/S, con un valor de mercado combinado de aproximadamente 305.60M, lo que representa el 9.08% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -0.74%.
¿Cuál es la mayor fuente de ganancias de Novo Nordisk A/S?
El FY2025Q2, el segmento empresarial Total GLP-1 generó la ganancia más alta para Novo Nordisk A/S, ascendiendo a 5.83B y representando el 49.92% de la ganancia total.
